Opinion
Brexanolone approval ‘marks an important milestone’
The NIMH calls the drug “a compelling example of successful bench-to-bedside translation of basic neuroscience findings to benefit patients.”
Joshua A. Gordon, MD, PhD
The NIMH calls the drug “a compelling example of successful bench-to-bedside translation of basic neuroscience findings to benefit patients.”